Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
US12016841B2 · kind B2 · utility
2Cited by
66References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2022 |
| Grant date | Jun 25, 2024 |
| Priority date | — |
| Expiry date | Mar 30, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.